Atypical B Cells Play a Central Role in COVID-19 Vaccine Response

Vaccines function by strengthening defenses against viruses that invade human bodies. Vaccination against COVID-19 teaches the human immune system's specialized B cells how to identify the virus. These B cells will promptly produce antibodies to fight and destroy the virus if subsequently contract COVID, but because the COVID-19 mRNA vaccines are so novel, the precise B cells that were activated remained unknown to researchers.

Now, in a study published in Nature Communications, a team of researchers from Osaka University has pinpointed the B cells responsible for boosting COVID-19 immunity after vaccination.

Several different types of B cells can be activated after vaccination, but it was not clear which B cells responded to the COVID-19 mRNA vaccine, we found that blood from people who were vaccinated against COVID-19 contained activated atypical B cells. These B cells are the main responders to the vaccine because they are highly correlated with the serum antibody response against the COVID-19 virus.

David Priest, Study Lead Author, Osaka University

Within the two known groupings of B cells, the scientists examined and identified individual cells using a technique known as mass cytometry. Classical B cells, which are prevalent in human blood, and non-classical B cells are these two types of B cells. The activated atypical cells that were recently found belong to the non-classical group. The investigators also discovered these cells in the blood of COVID-19-infected patients.

Activated atypical B cells provide a new way to assess how well people respond to COVID-19 vaccination. They also give us a new understanding of the underlying biology of mRNA vaccination. Now that we know these B cells are the primary responders to mRNA vaccines, we can work toward targeting them in future vaccine designs.”

James Wing, Study Senior Author, Osaka University

With the assistance of this study, researchers may be able to create better candidate vaccines and updates for the COVID-19 vaccine to help avert future pandemics.

Source:
Journal reference:

Priest, D. G., et al. (2024) Atypical and non-classical CD45RBlo memory B cells are the majority of circulating SARS-CoV-2 specific B cells following mRNA vaccination or COVID-19. Nature Communications. doi.org/10.1038/s41467-024-50997-4.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Swabbing Technique Reveals Diversity of Immune Cells in the Upper Airway